Treatment and Sequencing Strategies for EGFR-Mutated Non–Small Cell Lung Cancer
Key Points
- Management of epidermal growth factor receptor (EGFR) exon 20 insertions has advanced significantly in recent years, but challenges in treatment selection and sequencing remain.
- Amivantamab plus carboplatin-pemetrexed is currently the only combination approved for first-line treatment of patients with EGFR exon 20 insertions, pending approvals of sunvozertinib and zipalertinib in this setting.
- Clinical trials of amivantamab, sunvozertinib, and zipalertinib tend to feature a crossover design, making it difficult to determine overall survival benefit.
- Mutations such as C797S can present after progression on third-generation tyrosine kinase inhibitors (TKIs) or targeted therapies for EGFR exon 20 insertions.
In this interview, oncologists Lyudmila Bazhenova, MD, of UC San Diego Health, and Elaine Shum, MD, of NYU Langone Health, discuss the management of EGFR exon 20 insertions, a genetic biomarker in non–small cell lung cancer (NSCLC). The discussion covers findings presented at the 2026 World Conference on Lung Cancer (WCLC), which took place September 12 to 15 in Seoul, South Korea, including available data on progression-free survival (PFS) and overall survival (OS), as well as challenges related to sequencing.
A Potentially Changing Treatment Landscape
Despite recent advances in clinical knowledge of EGFR exon 20 insertion mutations, treatment selection and sequencing remain challenging due to a lack of data. “This is hard because we do not have any head-to-head trials, and we will never have any head-to-head trials,” Dr. Bazhenova said.
Currently, the only approved combination for first-line treatment of patients with EGFR exon 20 insertions is amivantamab plus carboplatin-pemetrexed, as demonstrated in the phase 3 PAPILLON trial.
However, sunvozertinib, which was approved in July 2025 as second-line treatment for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, is being evaluated for first-line treatment. Zipalertinib has not yet earned FDA approval for first-line or subsequent use, but an application for first-line use is being submitted. Approval of either drug could significantly impact the landscape, according to Dr. Bazhenova: “We’ll have to make choices.”
Lack of Data on CNS Activity
The first-line studies examining amivantamab, sunvozertinib, and zipalertinib feature crossover, making it difficult to determine the OS benefit. “We have to do a cross-trial comparison looking at response rate and progression-free survival to try to understand what’s the right sequencing,” Dr. Bazhenova said. The amivantamab combination and sunvozertinib yielded similar 18-month OS rates.
However, many trials appear to lack data on central nervous system (CNS) activity, according to Dr. Bazhenova. One exception is the phase 2 REZILIENT trial, in which zipalertinib demonstrated clinically meaningful CNS activity in patients with EGFR exon 20 insertion–positive NSCLC and active brain metastases.
The results helped provide some clarity, Dr. Bazhenova said: “If a patient has CNS metastasis and zipalertinib is available, I might lean toward zipalertinib. If a patient does not have CNS metastasis, I think I’ll have to rely on patient preference,” provided both amivantamab plus carboplatin-pemetrexed and sunvozertinib are available.
The Challenge of Sequencing With TKIs
Oncologists then face the hurdle of sequencing, particularly when dealing with mutations such as C797S, which can emerge after progression on third-generation TKIs or targeted therapies for EGFR exon 20 insertions. “It’s very unlikely” that zipalertinib and sunvozertinib will work unless the dosage has to be reduced for toxicity, according to Dr. Bazhenova.
“We know that efficacy post amivantamab is lower with sunvozertinib and zipalertinib,” she said, “but we don’t know the opposite sequence because TKIs were developed after amivantamab.” Therefore, it’s difficult to determine the efficacy of a TKI followed by amivantamab.
Disease Management When Navigating Unknowns
Myriad unknowns remain regarding the treatment of EGFR exon 20 insertion mutations in patients with NSCLC. Although there is “no perfect answer,” according to Dr. Bazhenova, three components should be prioritized: patient selection, patient preference, and brain metastases.
Finally, the experts emphasized the importance of an accurate diagnosis in ensuring optimal management. “You cannot do a liquid biopsy,” Dr. Bazhenova said, citing a 30% false-negative rate. Instead, providers should rely on next-generation sequencing and avoid assuming that all EGFR mutations are created equal: “You need to know the subtype you are treating.”